Webinar Now Available: Delivery of Oncolytic Immunotherapy by MSCs Enhances CAR-T Cell Anti-Tumor Activity

Chimeric antigen receptor (CAR) T cells hold great promise for targeting and fighting cancer. However, their efficacy in solid tumors has been below expectations, as the tumor microenvironment (TME) limits their infiltration and produces a range of immune-inhibitory molecules to deactivate T cells. Researchers are developing new strategies to enhance CAR-T cell therapy for solid tumors by disrupting the TME and promoting T cell persistence. In this webinar, Katie McKenna, PhD, will discuss how she uses CAR-T cells in combination with mesenchymal stromal cells that deliver engineered adenoviruses to stimulate the immune response in the TME.

Topics covered:

  • Targeting non-small cell lung cancer using a cell carrier system to deliver an oncolytic and immunostimulatory adenovirus
  • Efficacy of oncolytic virotherapy in 3D cell culture and in vivo
  • Assessing T cell functionality with single-cell proteomics

Watch the on-demand webinar below:

Share This Article
Subscribe to Follow the Data

Weekly email to keep you at the forefront of single-cell & multiplexed proteomics.

Your data is secure and you can unsubscribe anytime. Privacy Policy.